Seasoned industry executive with decades of success in drug discovery, development, regulatory approvals and commercialization will lead Nereid's work to advance multiple programs towards the clinic

经验丰富的行业主管在药物发现，开发，监管审批和商业化方面取得了数十年的成功，将领导Nereid的工作推动多个项目进入诊所

BOSTON, Nov. 13, 2023 /PRNewswire/ -- Nereid Therapeutics, a biotechnology company that is discovering new disease treatments by applying pioneering research and technologies to biomolecular condensates, announced today that Michael Kauffman, M.D., Ph.D., has joined the company as President and Chief Executive Officer.

波士顿，2023年11月13日/PRNewswire/-Nereid Therapeutics，一家生物技术公司，通过将开创性研究和技术应用于生物分子缩合物来发现新的疾病治疗方法，今天宣布Michael Kauffman博士已加入该公司担任总裁兼首席执行官。

Dr. Kauffman will also join the Nereid Board of Directors. Spiros Liras, Ph.D., a venture partner at Apple Tree Partners (ATP) who has been acting CEO of Nereid since the company was created by ATP in late 2020, will continue to serve on Nereid's Board of Directors and the company's Scientific Advisory Board..

考夫曼博士也将加入Nereid董事会。Spiros Liras博士是Apple Tree Partners（ATP）的风险合作伙伴，自2020年底由ATP创建以来一直担任Nereid的首席执行官，将继续担任Nereid的董事会和公司的科学顾问委员会。。

'We are delighted to welcome Michael to Nereid at a pivotal juncture when, having demonstrated translatability of chemical matter that modulates liquid-liquid phase separation behavior to disease-relevant cellular phenotypes, we are now rapidly progressing several programs addressing high-value targets in cancer and other diseases,' Dr.

“我们很高兴欢迎Michael在关键时刻欢迎Nereid，因为我们已经证明了调节液-液相分离行为的化学物质对疾病相关细胞表型的可译性，我们现在正在迅速开展几个解决癌症高价值目标的计划。和其他疾病，“博士。

Liras said. 'Michael brings to Nereid the right energy at the right time. He combines proven experience in leading teams delivering lifesaving therapies from the laboratory to patients, deep expertise in all aspects of industry, and a drive and passion to apply Nereid's groundbreaking science to achieve significant medical breakthroughs.'.

利拉斯说。'迈克尔在正确的时间带来了正确的能量。他结合了从实验室向患者提供救生疗法的领先团队的经验，在行业各个方面的深入专业知识，以及应用Nereid开创性科学以实现重大医疗突破的动力和激情。

Over a career in biopharmaceuticals spanning nearly three decades, Dr. Kauffman has led organizations through the discovery, development, and commercialization of novel drugs, including three FDA- and EMA-approved anti-cancer drugs: Velcade®, Kyprolis®, and Xpovio®. Most recently, he spent more than a decade as CEO and co-founder of Karyopharm.

Kauffman博士在近三十年的生物制药行业中领导组织通过新药的发现，开发和商业化，包括三种FDA和EMA批准的抗癌药物：Velcade®，Kyprolis®和Xpovio®。最近，他作为Karyopharm的首席执行官和联合创始人花了十多年的时间。

Prior to that, he was Chief Medical Officer (CMO) and then a clinical consultant for the Kyprolis® approval at Onyx Pharmaceuticals (subsequently acquired by Amgen). He has also served as a board member and then CMO of Proteolix, Operating Partner at Bessemer Venture Partners, and CEO of Epix Pharmaceuticals and Predix Pharmaceuticals (which was acquired by Epix).

在此之前，他是首席医疗官（CMO），然后是Onyx Pharmaceuticals（随后被Amgen收购）的Kyprolis®批准的临床顾问。他还曾担任Proteolix的董事会成员，然后是Bessemer Venture Partners的运营合作伙伴，以及Epix Pharmaceuticals和Predix Pharmaceuticals（被Epix收购）的首席执行官。

Earlier in his career, he held leadership positions at Millennium Pharmaceuticals and Biogen. He currently chairs the boards of BiVictriX Therapeutics and Incendia Therapeutics and serves on the Boards of Verastem Oncology, Kezar Life Sciences, and Adicet Bio. He is licensed to practice medicine in Massachusetts and completed his M.D.

在他职业生涯的早期，他在Millennium Pharmaceuticals和Biogen担任领导职位。他目前担任BiVictriX Therapeutics和Incendia Therapeutics的董事会成员，并担任Verastem Oncology，Kezar Life Sciences和Adicet Bio的董事会成员。他获准在马萨诸塞州执业医学并完成他的博士学位。

and Ph.D. degrees at Johns Hopkins, followed by residency at Beth Israel Hospital and fellowship at Massachusetts General Hospital, both affiliated with Harvard Medical School..

在约翰霍普金斯大学获得博士学位，随后在贝斯以色列医院居住，并在哈佛医学院附属马萨诸塞州总医院获得奖学金。。

'This is a transformational time to join Nereid as we enter a new phase of development and advance multiple programs in oncology and neurodegeneration towards the clinic,' Dr. Kauffman said. 'I look forward to working alongside this highly talented team who are pioneers in the novel, exciting and highly physiologically relevant field of biomolecular condensate science, which is the core of Nereid's approach to drug discovery and development.'.

考夫曼博士说：“当我们进入一个新的发展阶段，并将肿瘤学和神经退行性疾病的多个项目推向临床时，这是加入Nereid的转型时期。”我期待着与这个极具才能的团队合作，他们是生物分子凝聚科学这一新颖，令人兴奋和高度生理相关领域的先驱，这是Nereid药物发现和开发方法的核心。

Dr. Kauffman and other members of the Nereid leadership team will be onsite for meetings at the 42nd Annual J.P. Morgan Healthcare Conference taking place January 8-11, 2024, in San Francisco, CA.

Kauffman博士和Nereid领导团队的其他成员将现场参加2024年1月8日至11日在加利福尼亚州旧金山举行的第42届年度J.P.Morgan医疗会议。

About Nereid Therapeutics

关于Nereid疗法

Nereid Therapeutics, an ATP company, is discovering new disease treatments using proprietary state-of-the-art technologies for generating, visualizing, and measuring liquid-liquid phase separation and the resulting biomolecular condensates. Based on groundbreaking discoveries and technologies pioneered by 2023 Breakthrough Prize winner Cliff Brangwynne, Ph.D., Nereid applies leading expertise in soft matter physics and cell biology to pioneer completely new ways to fight intractable diseases.

ATP公司Nereid Therapeutics正在使用专有的最先进技术发现新的疾病治疗方法，用于生成，可视化和测量液-液相分离和由此产生的生物分子缩合物。基于2023年突破奖获得者Cliff Brangwynne博士开创的开创性发现和技术，Nereid运用软物质物理学和细胞生物学方面的领先专业知识，开创了抗击顽固性疾病的全新方法。

For more information, visit nereidtx.com..

欲了解更多信息，请访问nereidtx.com。。

SOURCE Nereid Therapeutics

来源Nereid疗法